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S U M M A R Y
Tuberculosis (TB) remains the deadliest infectious disease. The widely used bacille Calmette–Gue´rin
(BCG) vaccine offers only limited protection against TB. New vaccine candidates for TB include subunit
vaccines and inactivated whole-cell vaccines, as well as live mycobacterial vaccines. Current
developments in TB vaccines are summarized in this review.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).1. Introduction
According to a recent analysis, tuberculosis (TB) has killed one
billion people over the last 200 years, more victims than from
smallpox, malaria, plague, influenza, cholera, and AIDS together.1
Indeed towards the end of the 19th century, one in five of all deaths
was caused by TB.2 Although TB is considered a disease of the past
in some circles, it remains the deadliest contagious disease
globally. In 2015, 10.4 million new cases of active TB were
recorded, resulting in 1.8 million deaths (World Health Organiza-
tion, WHO).3
Approximately two billion people are infected with the
causative agent, Mycobacterium tuberculosis, but only a small
proportion of those individuals living with a latent TB infection
(LTBI) are at risk of developing active disease (somewhere in the
order of 10% over a lifetime).4 This is because our immune system
is capable of containing the pathogen in a dormant stage.5
However, since the immune response fails to achieve sterile
eradication, individualswith LTBI are at risk of developing TB later
in life.
TB reactivation is greatly accelerated by co-infection with HIV.3
Of the 15 million individuals suffering from co-infection with HIV
andM. tuberculosis, 1.2millionhave developed TB in 2015, rendering
HIV co-infection a major driving force in the TB pandemic. An* Corresponding author. Tel.: +49 30 28460 502.
E-mail address: Kaufmann@mpiib-berlin.mpg.de (Stefan H.E. Kaufmann).
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).additional complication is the increasing incidence of multidrug-
resistant (MDR)-TB[15_TD$DIFF] annually; this accounts for half a million new
cases with only a 50% chance of cure by drug treatment. Globally
some 50 million individuals are already latently infected with MDR
M. tuberculosis, creating a remarkable resource for future cases of
active TB with insufficient treatment options.3[14_TD$DIFF] Nevertheless, the
WHOhas vowed to reduce TBmorbidity by 90% and TBmortality by
95% by 2035.6 This ambitious goal can only be accomplished
successfully if more rapid diagnostics, new drugs for shorter
therapy, and new vaccines to prevent pulmonary TB become
available.6 A short up-to-date overview of vaccines is provided here.
2. The disease and the pathogen
TB is primarily a disease of the lung, which serves as the port of
entry and site of disease manifestation.7 M. tuberculosis is
transmitted by aerosol; if these bacteria reach the alveoli in the
deeper lung, they are engulfed by alveolar macrophages and
interstitial dendritic cells. These antigen-presenting cells transport
M. tuberculosis to draining lymph nodes, where T lymphocytes are
stimulated. Although antibodies are produced abundantly in
response to M. tuberculosis infection, T-cells are generally
considered the main mediators of protection during natural
infection.7 Orchestrated by T-cells, solid granulomas are formed
in the lung parenchyma, where M. tuberculosis is contained in a
persistent stage.8 Such solid granulomas are present in the two
billion individuals with LTBI. Active disease emerges when
granulomas lose their sophisticated structure and become necroticciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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tuberculosis reduces its metabolic and replicative activity to
become dormant.9 However, in caseous granulomas,M. tuberculo-
sis reactivates its metabolism and replicates to reach high
numbers. Rupture of a caseous granuloma allows for M.
tuberculosis dissemination to other tissue sites and to the
environment. Expectoration of cellular material containing M.
tuberculosis serves as the source of disease transmission.7
Although TB has long been considered to have two clearly
defined states (LTBI and active TB disease), recent evidence
suggests the existence of awhole spectrum of disease ranging from
LTBI to active TB.10
3. The current vaccine and future candidates
A vaccine against infant TB was introduced in 1921 by the
French scientists Albert Calmette and Camille Gue´rin, which was
accordingly named bacille Calmette–Gue´rin (BCG). This vaccine is
now widely used to prevent severe forms of extrapulmonary TB
such asmiliary TB in infants.11,12 However, BCG fails to prevent the
most common form of disease – pulmonary TB – at any age.11,12
BCG is an attenuated strain ofMycobacterium bovis, the etiological
agent of TB in cattle. Although it is well tolerated, it can
disseminate in immunocompromised individuals, notably HIV-
infected persons, causing a disease termed BCGosis.7 Accordingly,
BCG is not recommended for HIV-exposed neonates in several
countries.
Because of these limitations of BCG, novel TB vaccine candidates
have been developed, of which several have reached the clinical
trial pipeline. These TB vaccine candidates can be categorized into
the following: (1) preventive pre-exposure vaccines, which are
administered prior to first exposure to M. tuberculosis, typically toigure 1. Pipeline of major TB vaccines in clinical trials. RUTI and Vaccae are therapeutic vaccines; all other vaccines are preventive. For further explanations of antigens,
djuvants, and genetic modifications of the vaccines, see Tables 1–5. (Abbreviations: GSK, Glaxo Smith Kline; MPIIB, Max Planck Institute for Infection Biology; VPM, Vakzine
rojekt Management; SII, Serum Institute India; SSI, Statens Serum Institute; McMaster U, McMaster University; TBVI, Tuberculosis Vaccine Initiative; UOXF, University of




Oneonates; these are also known as priming vaccines; (2) preventive
post-exposure vaccines, which are targeted at adolescents and
adults with LTBI and prior BCG immunization; these are also
known as boosting vaccines; (3) therapeutic vaccines, which are to
be administered in adjunct with canonical TB drugs, notably to
persons at higher risk of developing recurrent disease.
Figure 1 provides an overview of the major TB vaccine
candidates in the clinical pipeline. Preventive vaccines come in
three generic types: subunit vaccines, viable whole-cell vaccines,
and inactivated whole-cell vaccines.
Subunit vaccines are composed of one ormore antigens that are
considered protective (Table 1). Often several antigens are
combined to improve vaccine efficacy. Yet, protectivity is generally
defined loosely and based on protection measured in one or more
experimental animal models. To increase protectivity, antigens are
either formulated with adjuvant or expressed by a recombinant
viral vector (Tables 2 and 3). A number of current vectored vaccine
candidates are based on recombinant adenovirus or vaccinia virus,
many of which express the antigen 85A (Table 3).13–22 Another
viral vectored vaccine against TB harnesses a replication-deficient
influenza virus expressingM. tuberculosis antigens. Some vectored
vaccines are being developed not only as BCG boosters, but also as
prime boost strategies comprising different viral vectors and/orM.
tuberculosis antigen combinations.20 The recombinant modified
vaccinia Ankara (MVA) vector expressing antigen 85A (MVA85A)
was one of the most advanced TB vaccines, but it failed to
demonstrate protection in a preventive pre-exposure phase IIb
trial.23 Generally, these subunit vaccines are given as a boost after a
BCG prime, with the aim of improving BCG-induced protection, i.e.
to increase efficacy and prolong duration.
Since pre-exposure vaccines are mostly confronted with
metabolically active M. tuberculosis, antigens for this type of
Table 5
Inactivated whole-cell mycobacterial vaccines
Name Inactivated organism Goal
[13_TD$DIFF] AR-901 Non-tuberculous Mycobacterium Prevention
Mw Mycobacterium indicus pranii Therapy
Vaccae Mycobacterium vaccae Therapy
RUTI Mycobacterium tuberculosis Therapy
Table 2
Adjuvants used for TB vaccines
Vaccine Name Composition
H1, H4, H56 IC31 Cationic [11_TD$DIFF]peptide/TLR9 agonist
H1 CAF01 Cationic liposome/immunomodulatory glycolipid
ID93 GLA-SE Oil in water emulsion/TLR4 agonist
M72 AS01E [12_TD$DIFF]Liposome/TLR4 agonist
TB, tuberculosis; TLR, toll-like receptor.
Table 3
Viral vectors used for TB vaccines
Name Vector




FLU Replication-deficient influenza virus (H1N1)
TB, tuberculosis.
Table 1
Antigens used in subunit TB vaccines
Vaccine Antigen Description
M72 Rv1196 PPE family member
Rv0125 Peptidase
H1 ESAT-6 Prominent antigen of Mtb
encoded in region of difference 1
Ag85B Mycolyl transferase
H4 TB10.4 Prominent TB antigen
Ag85B Mycolyl transferase
H56 H1+Rv2660c Dormancy antigen




Ad5Ag85A Antigen 85A Mycolyl transferase
MVA85A Antigen 85A Mycolyl transferase
Ad35 Antigen 85A Mycolyl transferase
TB10.4 Prominent TB antigen
Ag85B Antigen 85B Mycolyl transferase
TB-FLU-04L Antigen 85A Mycolyl transferase
TB, tuberculosis; PPE[8_TD$DIFF], proline, poline, [9_TD$DIFF] glutamate [10_TD$DIFF]residues; Mtb, Mycobacterium
tuberculosis.
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active replication and metabolism. These include the hybrid H1
and H4 vaccines.21,22 In contrast, post-exposure vaccines are
administered to persons with M. tuberculosis in a dormant stage
and need to include antigens expressed during latent infection.
Ideally, a combination of antigens in the form of fusion proteins is
administered to cover both active and latent stages. These so-
called multistage vaccines include H56, M72, and ID93
(Table 1).15,17,24
Viable vaccines were originally considered as replacement
vaccines only and given instead of BCG. Hence, their first target
population would be neonates (Table 4). The most advanced
vaccine candidate is the recombinant BCG vaccine, VPM1002,
which has shown a better safety and efficacy profile than standard
BCG in preclinical models.25 It has completed clinical phase I and
phase II trials in adults and neonates and is currently being
assessed in HIV-exposed neonates. It was shown that VPM1002Table 4
Viable TB vaccines
Name Vaccine Modification
VPM1002 BCG Chromosomal int
deletion of ureas
MTBVAC Mycobacterium tuberculosis Deletion of PhoP
TB, tuberculosis; BCG, bacille Calmette–Gue´rin.was well tolerated in adults with childhood BCG immunization,
and protected against TB in an experimental post-exposure mouse
model.26 Hence, this vaccine is currently being developed also as a
preventive post-exposure vaccine for adolescents and adults.
[17_TD$DIFF]Accordingly, a vaccination protocol has been submitted to prevent
recurrence of TB in previously cured TB patients. Even after
successful completion of drug treatment for active TB, over 10% of
patients experience recurrence and develop TB for a second time,
thus presenting a high risk group for vaccine trials. The second
viable vaccine candidate that has successfully completed a phase I
clinical trial is a double deletion mutant of M. tuberculosis termed
MTBVAC.27 [16_TD$DIFF]
3.1. Inactivated whole-cell mycobacterial vaccines for the prevention
of TB
Inactivated whole-cell mycobacterial vaccines used in a
multiple-dose schedule were shown to be effective preventive
vaccines in experimental models and in humans over 70 years ago,
but were not developed further after single-dose BCG became the
de facto preventive vaccine of choice.28,29 More recently SRL172,
an inactivated whole-cell vaccine derived from a non-tuberculous
Mycobacterium, was shown to be safe, well-tolerated, and
immunogenic in phase I and II trials. Efficacy was subsequently
documented in a phase III randomized, controlled, booster trial
among HIV-infected adults in Tanzania,30 making it the only new
TB vaccine in development for which efficacy in humans has been
demonstrated. The SRL172 master cell bank was used to develop
scalable manufacturing for the booster vaccine now known as
DAR-901. Safety and tolerability were demonstrated in a phase I
trial of the DAR-901 booster in adults primed with BCG in
childhood. DAR-901 induced both cellular and humoral responses
to mycobacterial antigens comparable to those observed with
SRL172, but did not result in conversion of the interferon gamma
release assay (IGRA). A randomized, controlled phase IIb trial is
now underway for the prevention of infection withM. tuberculosis
among adolescents in Tanzania.
A heat-inactivated whole-cell vaccine derived fromMycobacte-
rium vaccae (‘Vaccae’) is also being studied for the prevention of TB
after already being approved in China for the adjunctive treatment
of TB.31 The prevention trial was initiated in 2013 and was
designed to enroll 10 000 subjects with a positive tuberculin skin
test, but additional public information is not presently available
(Table 5).
Viable live-attenuated vaccines and inactivated vaccines are
termed whole-cell vaccines.32 Since it is not known what antigens
will induce protective immunity in humans, these polyantigenicegration of listeriolysin encoding gene (perforation of phagosomal membrane);
e gene (acidification of phagosome)
(transcription factor) and of fadD26 (phthiocerol dimycocerosate synthesis)
S.H.E. Kaufmann et al. / International Journal of Infectious Diseases 56 (2017) 263–267266vaccines have a greater likelihood than subunit vaccines of
including the critical epitopes required for protective efficacy.
3.2. Vaccines for the treatment of TB
Several vaccines are being developed to improve treatment
outcomes in active TB (reduce mortality or relapse rates). This is a
particular challenge in MDR-TB and extensively drug-resistant
(XDR)-TBwith extremely low cure rates of less than 50%, providing
a greater opportunity for identifying the therapeutic efficacy of an
investigational vaccine. The biological hypothesis is that additional
stimulation with mycobacterial antigens may further enhance the
immune response and improve bacterial killing. However, there
are experimental data suggesting that certain types of excessive
immune response might be detrimental in the immune control of
TB in humans.33,34
Mycobacterium indicus pranii (Mw) is an inactivated non-
tuberculous mycobacterial vaccine that has been studied as an
adjunct to therapy for leprosy35 (Table 5). A phase II study ofMwas
an adjunct to therapy for TB has been completed and is being
analyzed. A preclinical study of Mw administration by the aerosol
route will examine immune responses in guinea pig and mouse
models.
RUTI is a vaccine being developed to improve the outcomes in
the treatment of both LTBI and TB disease and to reduce exposure
to antibiotics (Table 5). Its mechanism of action is based on the
induction of a polyantigenic cellular response to non-replicating
bacilli contained in detoxified cell wall nano-fragments of M.
tuberculosis. A phase I trial demonstrated safety and immunoge-
nicity and a phase II trial showed safety and immunogenicity in
both HIV-negative and HIV-positive volunteers with LTBI.36 A
phase IIa trial is planned to investigate the safety and immunoge-
nicity of RUTI therapeutic immunization in patients with MDR-TB.
4. Concluding remarks
Until recently the development of new vaccines against TB was
directed towards containingM. tuberculosis by prolonging LTBI and
blocking active TB disease.4,5 Although an effective vaccine to
prevent TB disease would be an applaudable achievement, the
sterile elimination or prevention ofM. tuberculosis infection would
ultimately be preferred. Although the biological mechanisms that
might lead to sterile M. tuberculosis elimination or the prevention
ofM. tuberculosis infection are not known, recent evidence suggests
that BCG immunization is capable of preventing infection at least
in part.5,37 [2_TD$DIFF] As a result, some new vaccine candidates are now being
tested to determine whether they have efficacy in preventing M.
tuberculosis infection.38–40 These prevention of infection trials
employ IGRAs, which are based on a simple blood test to detect
infection.
Because TB is a poverty-related disease, cost matters. Hence, it
is critical to accelerate clinical trials and at the same time reduce
their cost. One option towards this goal is stratification based on
high-risk groups.41 [3_TD$DIFF] These include miners, who are at a markedly
elevated risk of developing TB, and patients with successfully
treated TBwho have a high rate of recurrent TB, as described above.
Alternatively, biomarkers that predict progression towards active
TB would allow the stratification of study participants at greatest
risk of developing active TB disease within the duration of a
standard clinical trial.41,42 Indeed, biosignatures that can predict
progression to active TB are currently being developed. These
signatures comprise changes in the gene expression of defined
markers at high sensitivity so that they most likely diagnose
subclinical incipient TB.43
Even though the development of an improved vaccine against TB
presents major challenges on several fronts, it is a goal worthpursuing. After all, an effective vaccine that prevents pulmonary TB
couldmakeamajor contribution to thegoalof reducingTBmorbidity
and mortality by 90% and 95%, respectively, by the year 2035.
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